A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia

Vormoor, B., Veal, G. J., Griffin, M. J., Boddy, A. V., Irving, J., Minto, L., Case, M., Banerji, U., Swales, K. E., Tall, J. R., Moore, A. S., Toguchi, M., Acton, G., Dyer, K., Schwab, C., Harrison, C. J., Grainger, J. D., Lancaster, D., Kearns, P., Hargrave, D. and Vormoor, J. (2016) A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia. Pediatric Blood and Cancer, . doi:10.1002/pbc.26351

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
UQ457568_OA.pdf Full text - (Open Access) application/pdf 289.47KB 0

Author Vormoor, B.
Veal, G. J.
Griffin, M. J.
Boddy, A. V.
Irving, J.
Minto, L.
Case, M.
Banerji, U.
Swales, K. E.
Tall, J. R.
Moore, A. S.
Toguchi, M.
Acton, G.
Dyer, K.
Schwab, C.
Harrison, C. J.
Grainger, J. D.
Lancaster, D.
Kearns, P.
Hargrave, D.
Vormoor, J.
Title A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia
Journal name Pediatric Blood and Cancer   Check publisher's open access policy
ISSN 1545-5009
1545-5017
Publication date 2016-11-01
Year available 2016
Sub-type Article (original research)
DOI 10.1002/pbc.26351
Open Access Status File (Publisher version)
Total pages 4
Place of publication Hoboken, NJ United States
Publisher John Wiley & Sons
Collection year 2018
Language eng
Abstract Aurora kinases regulate mitosis and are commonly overexpressed in leukemia. This phase I/IIa study of AT9283, a multikinase inhibitor, was designed to identify maximal tolerated doses, safety, pharmacokinetics, and pharmacodynamic activity in children with relapsed/refractory acute leukemia. The trial suffered from poor recruitment and terminated early, therefore failing to identify its primary endpoints. AT9283 caused tolerable toxicity, but failed to show clinical responses. Future trials should be based on robust preclinical data that provide an indication of which patients may benefit from the experimental agent, and recruitment should be improved through international collaborations and early combination with established treatment strategies.
Keyword Aurora kinase
AT9283
Leukemia
Pediatric
Phase I/II trial
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: HERDC Pre-Audit
Admin only - CHRC
Child Health Research Centre Publications
UQ Diamantina Institute Publications
 
Versions
Version Filter Type
Citation counts: Google Scholar Search Google Scholar
Created: Mon, 13 Feb 2017, 08:36:36 EST by Andrew Moore on behalf of UQ Diamantina Institute